Transarterial embolisation plus radiofrequency ablation vs radiofrequency ablation
Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether transarterial embolisation plus radiofrequency ablation changes serious adverse events (number of participants) compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
- Management of people with early‐ or very early‐stage hepatocellular carcinoma 2017 · Cochrane Headline outcomes onlyOR 2.11 [0.18, 25.35]2 studies · 84 participantsVery low